OTCMKTS:IDRSF - Idorsia Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$20.84
▼ -0.36 (-1.70%)

This chart shows the closing price for IDRSF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Idorsia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IDRSF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IDRSF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Idorsia in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $20.84.

This chart shows the closing price for IDRSF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Idorsia.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/27/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/27/2021JPMorgan Chase & Co.Reiterated RatingNeutral
10/12/2021Morgan StanleyReiterated RatingEqual Weight
10/12/2021HC WainwrightReiterated RatingBuy
9/16/2021Jefferies Financial GroupUpgradeHold ➝ Buy
7/28/2021JPMorgan Chase & Co.Reiterated RatingNeutral
7/19/2021BarclaysReiterated RatingOverweight
7/6/2021Credit Suisse GroupReiterated RatingOutperform
3/8/2021Credit Suisse GroupReiterated RatingOutperform
2/10/2021Morgan StanleyReiterated RatingEqual Weight
2/8/2021JPMorgan Chase & Co.Reiterated RatingNeutral
10/29/2020Morgan StanleyReiterated RatingEqual Weight
10/28/2020JPMorgan Chase & Co.Reiterated RatingNeutral
10/28/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
7/27/2020Morgan StanleyInitiated CoverageEqual Weight
7/8/2020JPMorgan Chase & Co.Initiated CoverageNeutral
6/15/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy
5/11/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform
4/20/2020HC WainwrightReiterated RatingPositive ➝ Buy
4/16/2020CitigroupInitiated CoverageBuy
1/28/2020The Goldman Sachs GroupInitiated CoverageNeutral
12/16/2019HC WainwrightInitiated CoverageBuy
(Data available from 10/27/2016 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2021

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Idorsia logo
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The firm targets patients who are suffering with Fabry disease, insomnia, Cerebral vasospasm associated with aSAH and systemic lupus erythematosus. The was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.
Read More

Today's Range

Now: $20.84
Low: $20.84
High: $20.99

50 Day Range

MA: $23.88
Low: $22.79
High: $25.87

52 Week Range

Now: $20.84
Low: $20.80
High: $33.25

Volume

585 shs

Average Volume

2,095 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Idorsia?

The following sell-side analysts have issued research reports on Idorsia in the last year: Barclays PLC, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., and Morgan Stanley.
View the latest analyst ratings for IDRSF.

What is the current price target for Idorsia?

0 Wall Street analysts have set twelve-month price targets for Idorsia in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Idorsia in the next year.
View the latest price targets for IDRSF.

What is the current consensus analyst rating for Idorsia?

Idorsia currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IDRSF will outperform the market and that investors should add to their positions of Idorsia.
View the latest ratings for IDRSF.

What other companies compete with Idorsia?

How do I contact Idorsia's investor relations team?

Idorsia's physical mailing address is Hegenheimermattweg 91, Allschwil, Basel-Landschaft (Basle. The company's listed phone number is (158) 844-0000. The official website for Idorsia is www.idorsia.com.